Psyence Biomedical Ltd
PBM4.070USD
+1.710+72.46%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
91.18KMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Psyence Biomedical Ltd Unternehmen
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Unternehmensinformationen
BörsenkürzelPBM
Name des UnternehmensPsyence Biomedical Ltd
IPO-datumDec 10, 2021
CEODr. Neil Maresky
Anzahl der mitarbeiter12
WertpapierartOrdinary Share
GeschäftsjahresendeDec 10
Addresse121 Richmond Street West Penthouse
StadtTORONTO
BörseNASDAQ Capital Market Consolidated
LandCanada
PostleitzahlM5H 2K1
Telefon17744604171
Website
BörsenkürzelPBM
IPO-datumDec 10, 2021
CEODr. Neil Maresky
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 9
Aktualisiert: Wed, Jul 9
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Parallel Advisors, LLC
38.56%
Sabby Management, LLC
4.52%
White Lion Capital LLC
1.76%
Citadel Advisors LLC
1.32%
Essential Planning, LLC
1.29%
Other
52.55%
Aktionäre
Aktionäre
Anteil
Parallel Advisors, LLC
38.56%
Sabby Management, LLC
4.52%
White Lion Capital LLC
1.76%
Citadel Advisors LLC
1.32%
Essential Planning, LLC
1.29%
Other
52.55%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
41.14%
Investment Advisor/Hedge Fund
4.52%
Venture Capital
1.83%
Hedge Fund
1.55%
Research Firm
0.64%
Corporation
0.48%
Other
49.83%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
45
357.80K
50.17%
+182.18K
2025Q1
45
167.96K
26.60%
+69.68K
2024Q4
82
948.20K
24.27%
+587.08K
2024Q3
88
169.92K
15.90%
-186.51K
2024Q2
92
159.62K
36.84%
-203.47K
2024Q1
96
157.41K
35.61%
-211.56K
2023Q4
88
18.95K
16.18%
-253.66K
2023Q3
87
16.58K
55.18%
-252.44K
2023Q2
86
17.96K
50.97%
-264.02K
2023Q1
85
19.55K
55.14%
-329.89K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Sabby Management, LLC
32.21K
4.52%
+32.21K
--
Mar 31, 2025
White Lion Capital LLC
12.55K
1.76%
+12.55K
--
Dec 04, 2024
Citadel Advisors LLC
9.45K
1.32%
+8.01K
+555.34%
Mar 31, 2025
Essential Planning, LLC
9.19K
1.29%
+9.19K
--
Dec 31, 2024
Virtu Americas LLC
4.58K
0.64%
+2.98K
+187.50%
Mar 31, 2025
AdvisorShares Investments, LLC
4.45K
0.62%
+1.07K
+31.71%
Mar 31, 2025
UBS Financial Services, Inc.
4.21K
0.59%
+2.62K
+164.01%
Mar 31, 2025
Launchpad Ignition Holdings LLC
2.00K
0.28%
+2.00K
--
Mar 31, 2024
Two Sigma Investments, LP
1.62K
0.23%
+1.62K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
AdvisorShares Psychedelics ETF
0.22%
AdvisorShares Psychedelics ETF
Anteil0.22%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Datum
Art
Verhältnis
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
